Trial Profile
Double-blind, Randomized, Vehicle-controlled Proof of Concept Study on the Efficacy, Safety, Local Tolerability, PK and Pharmacodynamics of Multiple Topical Administrations of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2015
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 29 Oct 2015 Time frame for primary endpoint has changed from 12 weeks to day 43 according to ClinicalTrials.gov.
- 29 Oct 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.